a Monkeys in Groups 2 and 3 were immunized as part of a previous study (CHAVI-ID NHP #109). In NHP #109, the monkeys were immunized with monomeric HIV-1 CH505 gp120 six times. Five days after the first four immunizations, the monkeys received an intravenous infusion of the indicated antibody at the dose (in mg/kg body weight) shown in parentheses. Subsequent immunizations of the monkeys in Groups 2 and 3 with HIV-1 CH505 gp120 were not accompanied by antibody treatment (see Supplementary Figure 1 and Online Methods).
b For Challenges 1-5, 3.5 animal infectious doses (AID 50 ) of SHIV-C5 were mixed with either BNM-III-170 (final concentration 300 µM) or an equivalent volume of DMSO. Within 30 minutes of preparation, the virus-compound mixtures were applied intrarectally in an atraumatic manner.
SHIV-C5 Challenges 1, 2 and 3 were each conducted 2-4 weeks after boosting the monkeys with the appropriate immunogen, either gp120 or human serum albumin. The monkeys were not immunized after Challenge 3. Thus, SHIV-C5 Challenges 4, 5 and 6 were conducted on monkeys that had last been immunized 17, 24 and 33 weeks earlier, respectively.
Supplementary Table 2 >30 µ g/ml 0.2 µ g/ml >30 µ g/ml <0.2 µ g/ml 6.5 µ g/ml >30 µ g/ml <0.2 µ g/ml <0.2 µ g/ml >30 µ g/ml >30 µ g/ml 
